scholarly journals Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)

2014 ◽  
Vol 45 (5) ◽  
pp. 1793-1801 ◽  
Author(s):  
PAUL TOREN ◽  
AMINA ZOUBEIDI
Keyword(s):  
Prostate Cancer ◽  
Akt Pathway ◽  
Challenges And Opportunities

Immunotherapy in prostate cancer: challenges and opportunities

Immunotherapy ◽  
2016 ◽  
Vol 8 (1) ◽  
pp. 69-77 ◽  
Author(s):  
Masanori Noguchi ◽  
Noriko Koga ◽  
Fukuko Moriya ◽  
Kyogo Itoh
Keyword(s):  
Prostate Cancer ◽  
Challenges And Opportunities

scholarly journals Oncotoxic Properties of Serotonin Transporter Inhibitors and 5-HT1A Receptor Ligands

2018 ◽  
Vol 19 (10) ◽  
pp. 3260 ◽  
Author(s):  
Jarosław Walory ◽  
Lidia Mielczarek ◽  
Małgorzata Jarończyk ◽  
Mirosława Koronkiewicz ◽  
Jerzy Kossakowski ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cytotoxic Activity ◽  
Cancer Cells ◽  
Serotonin Transporter ◽  
Receptor Agonist ◽  
Antagonistic Activity ◽  
Hek293 Cells ◽  
Akt Pathway ◽  
Prostate Cancer Cells ◽  
Receptor Ligands

The cytotoxic activity of several serotonin transporter (SERT) inhibitors and subtype of serotonin receptor 1A (5-HT1A receptor) ligands have been examined in androgen-insensitive human PC-3 prostate and neuroblastoma SH-SY5Y cancer cells. Almost all of the studied compounds (except 5-HT1A receptor agonist (2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT)) exhibited absolute cytotoxic activity against the examined cancer cells. The compound 4-Fluoro-N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]benzamide hydrochloride (S14506) that showed highest activity against neuroblastoma tumors was the 5-HT1A receptor agonist (although not alike other 5-HT1A receptor agonists). On the other hand, the compound 6-nitro-2-(4-undecylpiperazin-1-yl)quinoline hydrochloride (AZ07) that had the highest activity against PC-3 prostate cancer cells was a compound exhibiting antagonistic activity against the 5-HT1A receptor. Thus, compounds of oncotoxic properties S14506 and AZ07 should be evaluated further for their potential use in the prevention and treatment of cancer. Most of the 15 compounds tested exhibited either agonistic or antagonistic activity for both the cyclic adenosine monophosphate (cAMP) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) pathways in human embryonic kidney 293 (HEK293) cells that overexpress the 5HT1AR gene. However, compounds paroxetine, N-Ac-paroxetine and 2-[4-(cyclobutylmethyl)piperazin-1-yl]-6-nitroquinoline hydrochloride (AB22) simultaneously exhibited antagonistic activity on the cAMP pathway and agonistic activity on the ERK1/2 pathway. Fluoxetine relative to compound AZ07 had almost three times lower cytotoxic activity against PC-3 prostate cancer cells. However, the proapoptotic activity of fluoxetine compared to compound AZ07 is almost two times higher which would suggest that the cytotoxic activity of both compounds may be dependent on different cell death mechanisms. Compound S14506 was found to be an antagonist of the serine-threonine protein kinase B (Akt) pathway. Prosurvival Akt activity may be reversed by Akt antagonists. Therefore, the antagonistic activity of S14506 on the Akt pathway may evoke caspase-3 expression and cytotoxicity. It appears that one should not expect a straightforward relationship between the activation of particular serotonergic pathways by selective serotonin reuptake inhibitors (SSRIs) and 5-HT1A receptor ligands and their cytotoxic or cytoprotective activity. Additionally, nuclear transcription factor κB (NF-κB), which may be involved in 5-HT-dependent biochemical pathways by coordinating different subunits in the formation of a dimer, may regulate the transcription of different transduction pathways. Therefore, it can be suggested that the mechanism of the cytotoxic activity of certain compounds (serotonergic against nonserotonergic) may depend on the compound and cancer type being examined. Docking studies showed that S14506, buspirone and spiperone bind in similar ways in the 5-HT1A receptor model and interacted with similar 5-HT1A receptor residues. S14506 and spiperone were found to be located closer to both phenylalanines in TM6 than buspirone, thus exhibiting more antagonist binding modes.

scholarly journals Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Seung-Hyun Shin ◽  
Ga Young Lee ◽  
Mingyu Lee ◽  
Jengmin Kang ◽  
Hyun-Woo Shin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Metastasis ◽  
Akt Pathway ◽  
Aberrant Expression ◽  
Prostate Cancer Metastasis

Abstract 3504: Targeting the Akt pathway and HDAC signaling in prostate cancer

2011 ◽  
Author(s):  
Silvia Paesante ◽  
Marie Kiersten Miles ◽  
Holly Nguyen ◽  
Robert Vessella ◽  
Roberto Pili
Keyword(s):  
Prostate Cancer ◽  
Akt Pathway

Abstract 5040: Involvement of PI3K/Akt pathway in cadmium triggered aggressive prostate cancer

2019 ◽  
Author(s):  
Priyanka Kulkarni ◽  
Pritha Dasgupta ◽  
Nadeem S. Bhat ◽  
Yutaka Hashimoto ◽  
Sharanjot Saini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Akt Pathway ◽  
Aggressive Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document